Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab PK/Safety in Chinese Psoriasis Patients
NCT03073213Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2017
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ixekizumab in plaque psoriasis (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration of Ixekizumab (Single Dose) at Day 141, Area Under Concentration From Time Zero to Infinity of Ixekizumab (Single Dose) at Day 141 and 3 more. Started Apr 2017; status: completed.
02
Drugs
ixekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03073213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03073213.